Evidence map›Paper›PMID 30719689›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2019

Inhibitory role of transforming growth factor β2 in experimental autoimmune anterior uveitis.

Bharati Matta, Puran S Bora, Adam J Neuhouser, Nalini S Bora

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Role of CD4Clinical and experimental medicine · 2025
    Review
  3. Review
  4. Tregs in Autoimmune Uveitis.Advances in experimental medicine and biology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Bharati MattaDepartment of Ophthalmology, Jones Eye Institute, Pat and Willard Walker Eye Research Center, College of Medicine, University of Arkansas for Medical Sciences, 4301 West Markham, Mail Slot 523, Little Rock, AR, 72205, USA.
Puran S BoraDepartment of Ophthalmology, Jones Eye Institute, Pat and Willard Walker Eye Research Center, College of Medicine, University of Arkansas for Medical Sciences, 4301 West Markham, Mail Slot 523, Little Rock, AR, 72205, USA.
Adam J NeuhouserDepartment of Ophthalmology, Jones Eye Institute, Pat and Willard Walker Eye Research Center, College of Medicine, University of Arkansas for Medical Sciences, 4301 West Markham, Mail Slot 523, Little Rock, AR, 72205, USA.
Nalini S BoraDepartment of Ophthalmology, Jones Eye Institute, Pat and Willard Walker Eye Research Center, College of Medicine, University of Arkansas for Medical Sciences, 4301 West Markham, Mail Slot 523, Little Rock, AR, 72205, USA. NBora@UAMS.edu.
University of Arkansas for Medical Sciences · USFeinstein Institute for Medical Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeExperimental autoimmune anterior uveitis (EAAU) is a clinically relevant animal model for human idiopathic anterior uveitis (IAU). The role of the immunomodulator transforming growth factor β2 (TGF-β2) in EAAU pathology is unknown. In this study, we investigated the regulatory role of TGF-β2 in EAAU.

methodsEAAU was induced in male Lewis rats by footpad injection of melanin-associated antigen (MAA). TGF-β2 was administered intravenously (iv) in MAA-sensitized rats during the induction of EAAU, or after the clinical onset of uveitis. MAA-sensitized rats injected similarly with an equal volume of PBS served as control. Animals were examined daily between days 7 and 30 post-injection for the clinical signs of uveitis using slit lamp biomicroscopy. Animals were sacrificed at various time points and eyes were harvested for histological analysis to assess the course and severity of inflammation. For histopathological analysis, paraffin sections of harvested eyes were stained with hematoxylin and eosin. Popliteal lymph nodes (LNs) were used for CD4

resultsAdministration of recombinant TGF-β2 during the early stages of EAAU prevented the induction of uveitis. Compared to PBS, the presence of TGF-β2 in the cell culture significantly (p < 0.05) inhibited the proliferation of CD4

conclusionsTGF-β2 plays a critical role in regulation of intraocular inflammation in EAAU. Findings reported in this study improve our understanding of immunopathology of IAU and suggest that recombinant TGF-β2 may be a promising therapeutic agent for human IAU.

Indexed as

AnimalsAutoimmune DiseasesCell ProliferationDisease Models, AnimalInjections, IntraocularMaleRatsRats, Inbred LewRecombinant ProteinsT-LymphocytesTransforming Growth Factor beta2Uveitis, AnteriorRecombinant ProteinsTransforming Growth Factor beta2Anterior uveitisCD4+ T cellsExperimental autoimmune anterior uveitisInflammationTransforming growth factor β2T regulatory cells

Identifiers

PMID30719689
OpenAlexW2913671188

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.